MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Merck & Co (NY:MRK)

98.27 -1.99 (-1.98%)
Official Closing Price Updated: 7:00 PM EST, Dec 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Merck & Co

< Previous 1 2 3 4 5 6 7 8 9
...
26 27 Next >
News headline image
Merck Receives Positive EU CHMP Opinion for Expanded Use of WINREVAIR™ (sotatercept) in Adults with Pulmonary Arterial Hypertension (PAH, WHO* Group 1 Pulmonary Hypertension)
From Merck & Co., Inc.
Via Business Wire
News headline image
FDA Conditionally Approves Merck Animal Health's EXZOLT™ CATTLE-CA1 for the Prevention and Treatment of New World Screwworm (Cochliomyia hominivorax) Larvae (myiasis)
From Merck & Co., Inc.
Via Business Wire
Chronic Rare Diseases in an Aging America: Why HyBryte and Federal Policy Matter Now
Via Investor Brand Network
Topics Government
News headline image
Chronic Rare Diseases in an Aging America: Why HyBryte and Federal Policy Matter Now
From BioMedWire
Via GlobeNewswire
News headline image
Merck Showcases Data for Alzheimer's Disease Candidates MK-2214 and MK-1167 at CTAD 2025
From Merck Sharp & Dohme
Via Business Wire
News headline image
Merck to Participate in the Citi 2025 Global Healthcare Conference
From Merck & Co., Inc.
Via Business Wire
News headline image
Merck to Participate in the 8th Annual Evercore ISI HealthCONx Conference
From Merck Sharp & Dohme
Via Business Wire
Biotech Valuations Rise as New Clinical Platforms Show Progress
Via Investor Brand Network
News headline image
Biotech Valuations Rise as New Clinical Platforms Show Progress
From BioMedWire
Via GlobeNewswire
News headline image
Merck Data to be Presented at ASH 2025 Annual Meeting Showcase Continued Advancements in Hematology Pipeline and Novel Therapeutic Approaches
From Merck & Co., Inc.
Via Business Wire
News headline image
Merck Recommends Rejection of Tutanota’s “Mini-Tender” Offer
From Merck & Co., Inc.
Via Business Wire
News headline image
FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each with Padcev® (enfortumab vedotin-ejfv), as Perioperative Treatment for Adults with Cisplatin-Ineligible Muscle-Invasive Bladder Cancer
From Merck & Co., Inc.
Via Business Wire
News headline image
Merck Announces Positive Topline Results from the Pivotal Phase 3 Trial Evaluating Investigational, Once-Daily, Oral, Two-Drug, Single-Tablet Regimen of Doravirine/Islatravir (DOR/ISL) in Treatment-Naïve Adults with HIV-1 Infection
From Merck & Co., Inc.
Via Business Wire
News headline image
European Commission Approves Subcutaneous Administration of KEYTRUDA® (pembrolizumab) for All Adult Indications Approved in the European Union
From Merck & Co., Inc.
Via Business Wire
News headline image
Merck Announces First-Quarter 2026 Dividend
From Merck & Co., Inc.
Via Business Wire
News headline image
Merck’s WINREVAIR™ (sotatercept-csrk) Met Primary Endpoint in Phase 2 CADENCE Study in Adults With Combined Post- and Precapillary Pulmonary Hypertension (CpcPH) due to Heart Failure With Preserved Ejection Fraction (HFpEF)
From Merck & Co., Inc.
Via Business Wire
News headline image
Merck to Acquire Cidara Therapeutics, Inc., Diversifying Its Portfolio to Include Late-Phase Antiviral Agent
From Merck & Co., Inc.
Via Business Wire
News headline image
Merck to Participate in the Jefferies Global Healthcare Conference in London
From Merck & Co., Inc.
Via Business Wire
News headline image
Merck’s Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Adults with Heterozygous Familial Hypercholesterolemia (HeFH) in Phase 3 CORALreef HeFH Trial
From Merck & Co., Inc.
Via Business Wire
News headline image
Merck’s Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Phase 3 CORALreef Lipids Trial
From Merck & Co., Inc.
Via Business Wire
News headline image
Merck Enters into Research and Development Funding Agreement with Blackstone Life Sciences for Sacituzumab Tirumotecan (sac-TMT)
From Merck & Co., Inc.
Via Business Wire
News headline image
Merck Signs Agreement with Dr. Falk Pharma GmbH for Certain Development and Commercialization Rights to MK-8690 (PRA-052) an Investigational Anti-CD30 Ligand Monoclonal Antibody
From Merck & Co., Inc.
Via Business Wire
News headline image
Merck Foundation Launches $22 Million Initiative to Improve Cardiovascular Care in the U.S.
From Merck Sharp & Dohme
Via Business Wire
News headline image
Merck & Co., Inc., Rahway, N.J., USA Announces Third-Quarter 2025 Financial Results
From Merck & Co., Inc.
Via Business Wire
Nanomedicine Innovations Transforming Oncology Drug Delivery and Bioavailability
Via Investor Brand Network
News headline image
Nanomedicine Innovations Transforming Oncology Drug Delivery and Bioavailability
EQNX::TICKER_START (OTCQB:OTLC),(NASDAQ:IOVA),(NYSE:MRK),(NYSE:LLY),(NYSE:JNJ) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
Merck and Eisai Provide Update on Phase 3 LEAP-012 Trial in Unresectable, Non-Metastatic Hepatocellular Carcinoma
From Merck & Co., Inc.
Via Business Wire
News headline image
European Commission Approves KEYTRUDA® (pembrolizumab) as Part of a Treatment Regimen for Adults with Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC) Expressing PD-L1 (CPS >1)
From Merck & Co., Inc.
Via Business Wire
News headline image
Merck Announces KEYTRUDA® (pembrolizumab) Plus WELIREG® (belzutifan) Met Primary Endpoint of Disease-Free Survival (DFS) in Certain Patients With Clear Cell Renal Cell Carcinoma (RCC) Following Nephrectomy
From Merck & Co., Inc.
Via Business Wire
News headline image
Merck and Eisai Announce WELIREG® (belzutifan) Plus LENVIMA® (lenvatinib) Met Primary Endpoint of Progression-Free Survival (PFS) in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma
From Merck & Co., Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
26 27 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story